Fortrea Holdings (FTRE) Profit After Tax (2022 - 2026)
Fortrea Holdings (FTRE) posted Profit After Tax of -$23.6 million for Q1 2026, up 27.38% on a QoQ basis from -$32.5 million in Q4 2025, and up 95.81% year-over-year from -$12.1 million in Q1 2025.
Fortrea Holdings (FTRE) Profit After Tax (2022 - 2026) Analysis & Trends
Fortrea Holdings' Profit After Tax history runs 5 years deep, the most recent figure standing at -$23.6 million for Q1 2026.
- Quarterly Profit After Tax rose 95.81% year-over-year to -$23.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$446.9 million (up 38.27% YoY) and the FY2025 annual result came in at -$986.2 million, down 263.24% from the prior year.
- Profit After Tax was -$23.6 million for Q1 2026 at Fortrea Holdings, up from -$32.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at $60.6 million in Q3 2022 and bottomed at -$562.9 million in Q1 2025.
- A 5-year average of -$82.6 million and a median of -$21.0 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax soared 137.38% — and 2025, when it tumbled 673.81%.
- Fortrea Holdings' Profit After Tax stood at -$13.6 million in 2022, then plunged by 257.35% to -$48.6 million in 2023, then surged by 91.36% to -$4.2 million in 2024, then tumbled by 673.81% to -$32.5 million in 2025, then climbed by 27.38% to -$23.6 million in 2026.
- Business Quant data shows FTRE's Profit After Tax at -$23.6 million in Q1 2026, -$32.5 million in Q4 2025, and -$15.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Fortrea Holdings | 1.83 Bn | 1.68 Bn | 123.60 Mn | -23.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.60 Mn |
| Dec 31, 2025 | -32.50 Mn |
| Sep 30, 2025 | -15.90 Mn |
| Jun 30, 2025 | -374.90 Mn |
| Mar 31, 2025 | -562.90 Mn |
| Dec 31, 2024 | -4.20 Mn |
| Sep 30, 2024 | -18.50 Mn |
| Jun 30, 2024 | -138.40 Mn |
| Mar 31, 2024 | -101.00 Mn |
| Dec 31, 2023 | -48.60 Mn |
| Sep 30, 2023 | -14.00 Mn |
| Jun 30, 2023 | 32.00 Mn |
| Mar 31, 2023 | 19.10 Mn |
| Dec 31, 2022 | -13.60 Mn |
| Sep 30, 2022 | 60.60 Mn |
| Jun 30, 2022 | -85.60 Mn |